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Introduction
Migraine remains poorly treated with few effective pre-
ventive medications available.
Aim
We evaluated the efficacy and safety of LY2951742, a
fully humanized monoclonal antibody to Calcitonin
Gene-Related Peptide (CGRP) for migraine prevention.
Methods
Eligible subjects with 4-14 migraine headache days
(MHD) per month were randomized in a double-blind
manner to LY2951742 or placebo, administered subcuta-
neously, every other week over a 12-week period. The
primary endpoint was the mean change from baseline in
number of MHD in the last 28 day period (month
three); secondary end points included the mean change
in headache days, migraine attacks, and the 50% respon-
der rate at month 3.
Results
Mean change in MHD (primary) was -4.2 vs. -3.0 for
LY2951742 (n=107) and placebo (n=110), respectively (p =
0.003). LY2951742 was superior to placebo for all second-
ary endpoints including headache days -4.9 vs. -3.7 (p =
0.0117), migraine attacks -3.1 vs. -2.3 (p = 0.0051), and
50% responder rate, 70% vs. 45% (OR 2.88 [CI 1.78;4.69]).
An exploratory endpoint of complete response (100%
reduction in MHD in month 3) was 31.6% vs. 17.3%
(OR 2.16 [CI 1.24;3.75]) for LY2951742 and placebo,
respectively. Adverse events reported by approximately
≥5% of LY2951742-treated patients and more frequently
with LY2951742 than placebo included upper respiratory
tract infections, injection site pain, neck pain, abdominal
pain, dizziness, injection site erythema, rash, hypertension
and pain in extremity.
Conclusions
Treatment with LY2951742 demonstrated significant
separation from placebo on the primary and secondary
endpoints. LY2951742 appeared to be safe and well-
tolerated.
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